{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:27:55Z","timestamp":1787833675564,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.eururo.2016.03.017","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T15:36:25Z","timestamp":1458401785000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Christopher P.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Andriole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choung-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Noonberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank","family":"Mansbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Perabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.03.017_bib0090","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. GLOBOCAN Web site. http:\/\/globocan.iarc.fr."},{"key":"10.1016\/j.eururo.2016.03.017_bib0095","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Web site. http:\/\/seer.cancer.gov."},{"key":"10.1016\/j.eururo.2016.03.017_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2016.03.017_bib0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.critrevonc.2014.01.003","article-title":"Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases","volume":"91","author":"Zustovich","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2016.03.017_bib0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.03.017_bib0115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.03.017_bib0120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.03.017_bib0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.03.017_bib0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2016.03.017_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.03.017_bib0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.03.017_bib0145","doi-asserted-by":"crossref","unstructured":"Ryan C, Smith M, Fizazi K, et al. Final overall survival analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Presented at European Society for Medical Oncology 2014 Congress; September 28, 2014; Madrid, Spain. Abstract 753O.","DOI":"10.1093\/annonc\/mdu336.1"},{"key":"10.1016\/j.eururo.2016.03.017_bib0150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2016.03.017_bib0155","doi-asserted-by":"crossref","first-page":"abstr LBA2","DOI":"10.1200\/jco.2014.32.18_suppl.lba2","article-title":"Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial","volume":"32","author":"Sweeney","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.03.017_bib0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.03.017_bib0165","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.03.017_bib0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/annonc\/mdu510","article-title":"Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial","volume":"26","author":"Cella","year":"2015","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816002748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816002748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T01:02:38Z","timestamp":1668646958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0302283816002748"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.03.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}